For life sciences companies that focus on clinical and product development, the disruptions created by the COVID-19 crisis have been sweeping. When the pandemic hit in early 2020, many pharmaceutical and biotechnology companies across the globe quickly pivoted operations to focus on developing COVID-19 drugs, therapeutics, and vaccines.